Page 516«..1020..515516517518..530540..»

Support for blood cancer patients is thin. This needs to change – TimesLIVE

Posted: April 6, 2022 at 1:56 am

While South Africans recently observed Human Rights Day, the notion of basic human rights continues to be a global topic of contention, particularly as the World Health Organisation (WHO) asserts that health is a fundamental human right.

The organisations director-general, Dr Tedros Adhanom Ghebreyesus, expands on this notion well, explaining that enjoying the highest attainable standard of health is a fundamental right of every person.

In SA, the publics right to health is protected by Section 27a of the constitution, which declares that everyone has the right to access to healthcare services. While this is embedded in our rights as citizens, it is often our misinterpretations and the failures of providers that lead to the collapse of such rights.

The right to adequate healthcare is particularly relevant when addressing dread diseases such as cancer, where specialised medical interventions can prolong or save a life. Most notable is the need for interventions to address more pressing cancers, such as hematologic malignancies, or blood cancers. These are orphan diseases and are not nearly as common as the more predominant types, such as breast and prostate cancer.

All cancers require immediate intervention, but once blood cancer is detected in a patient, the clock starts ticking to seek appropriate treatment. While conventional intensive treatments such as chemotherapy have proven useful, they can only drive the disease into remission and patients have a high likelihood of relapse.

Treatments such as blood stem cell therapy have a high probability of eradicating the disease. However, there have been challenges to the procedure in SA.

The department of health promulgated the Medical Schemes Act 131 in 1998, which featured an annexure that defines what stem cell transplantation is and how patients would qualify. It also noted that the act would be reviewed and updated every two years. However, this has not happened.

See the original post:
Support for blood cancer patients is thin. This needs to change - TimesLIVE

Posted in Stem Cell Therapy | Comments Off on Support for blood cancer patients is thin. This needs to change – TimesLIVE

Addition of Lenalidomide to SOC Shows Feasibility, Safety in MDS, AML and CMML – Targeted Oncology

Posted: April 6, 2022 at 1:56 am

AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.

Following allogenic stem cell transplant (allo-SCT), lenalidomide (Revlimid) at a dose of 5 mg a day can be added safely to the standard of care combination of azacitidine (Vidaza) and donor lymphocyte infusions (DLI) as salvage therapy for patients with relapse of myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) with MDS-related changes, results from the phase 2 AZALENA study (NCT02472691) show.1

The open-label, single-arm, multicenter study investigated the safety and feasibility of lenalidomide in addition to the standard therapy of azacitidine and DLI as first salvage therapy for this patient population.

We have seen encouraging response rates, duration of response and survival including patients with early and/or hematologic relapse in AZALENA. Azacitidine, lenalidomide and DLI favorable modulated the balance between GvHD and [graft-versus-leukemia; GvL] and is an efficient treatment option for patients with myeloid neoplasms relapsing after allogeneic stem cell transplantation which should be further investigated in randomized trials, stated Thomas Schroeder, MD, assistant professor, section head, Department of Internal Medicine, Division of Hematology/Oncology, medical director of Radiation Oncology, University of New Mexico, during an presentation of the data at the 48th Annual EBMT Meeting.

AZALENA enrolled 50 participants aged 18-99 with first relapse of de novo or therapy-related MDS, CMML or AML in various participating centers across Germany.2 Other requirements for inclusion in the study included possibility of DLI, no previous therapy for relapse after allo-SCT, an ECOG status of 0-2, and no uncontrolled infection at the time of enrolment.

Of the patients enrolled in the trial, the median age was 63 years. Forty-six percent of the patients with AML (n = 23), 48% with MDS (n = 24) and 6% with CMML (n = 3). A majority of patients (72%) were not in remission at the time of transplantation but received standard-dose conditioning (68%).

Patients included in the study received a median of 275 treatment cycles and were given azacitidine as a standard of care at 75 mg for 7 days every 28 days for up to 8 cycles. DLIs were then administered after cycle 4, 6 and 8 at a dose of 5-10x105CD3+/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI).

The investigational drug, lenalidomide, was also started on day 1 for 21 days every 28 days for 8 cycles at most. A starting dose of 2.5 mg of lenalidomide per day was given to the first 10 patients. If no dose limiting toxicity was observed at the time of a first interim analysis, the next 10 patients were to be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients were treated with 5 mg per day.

The primary end point of the study was to evaluate safety including the number, types, and severity of adverse events (AEs), graft versus host disease (GvHD) and hospitalization. The secondary end point of the study examined safety in regard to response, duration of response, and overall survival.

Findings revealed there to be an overall response rate of 56% (n = 28). The time to complete response was 113 days seen in the 50% of patients with a median of 4 cycles. A total of 20 patients with CR had received DLI. Of the patients included, 6% showed a partial response. The median OS for all patients was 21 months and the 1-year OS rate was 65%. Patients who achieved remission had a superior survival versus 9.7 months.

In regard to toxicity, almost a third of the patients had either grade 3 or 4 neutropenia (30%) or thrombopenia (38%) at the time of study entry. Of the 275 treatment cycles, 246 included 89% of patients receiving the combination therapy, and in 29 cycles, lenalidomide was omitted in 5 patients (11%).

Lenalidomide-related AEs which were grade 3 or higher were seen in some patients including 38% of patients (n = 19) having to be hospitalized at some point in the duration of the trial. Grade 3 AEs seen in patients included infections (20%), febrile neutropenia (10%), gastrointestinal disorders (6%), and nervous system disorders (6%). Grade 4 AEs consisted of infections (4%) and febrile neutropenia (2%).

Looking at GvHD, 30% of the patients suffered from acute GvHD and 38% chronic GvHD. Time to GvHD onset was approximately 112 days the majority of patients with GvHD (77%, n = 20) had received DLI.

See original here:
Addition of Lenalidomide to SOC Shows Feasibility, Safety in MDS, AML and CMML - Targeted Oncology

Posted in Stem Cell Therapy | Comments Off on Addition of Lenalidomide to SOC Shows Feasibility, Safety in MDS, AML and CMML – Targeted Oncology

Facebook and radicalisation: how can we regulate the internet to prevent harm? – Stuff

Posted: April 6, 2022 at 1:55 am

Oh, hi! Long time no see! My name is Robbie and Im another white man behind a desk, and things are pretty bad, huh?

In case you never go outside and have these videos sent to your door on a USB delivered by a carrier pigeon, you might have missed a wee bit of a scuffle outside New Zealand Parliament. It turns out there were some folks there with some really interesting opinions! Would you like to meet them? I bet you wouldnt!

Its time to play Meet That Protestor!

[Spanish Flea starts playing. Robbie pulls out a thin old-school microphone.]

Bachelorette number one is Chantelle Baker! With nearly 100,000 Facebook followers, Chantelle well outnumbers her dad, former leader of the New Conservatives, who only has 52,000 Facebook followers. Embarrassing! Chantelle enjoys sharing live streams of peace and love that include other protestors saying, Were not leaving till we hang them. Baker disavows those protestors in the strongest possible terms by joining them and supporting their protest.

READ MORE:* The outing of an Internet troll showed women can win* The internet is no safer three years on from the Christchurch terror attack * We have failed to rein in social media's misinformation

Bachelor number two! Its the Freedom and Rights Coalition with 44,000 followers on Facebook. No wonder people love them! After all, they stand for Freedom and Rights. This might be Brian Tamakis group, but unfortunately, he cant make it because of all that breaking the law business. But dont worry! He could be your pen pal! The man writes beautiful letters warning New Zealanders that were heading down the path of UN ideology of socialism. After a walk down the path of socialism, why not go for a romantic walk down the beach with the Freedom and Rights Coalition!

Supplied/WhiteManBehindADesk

Satirist Robbie Nicol AKA White Man Behind A Desk details Facebook and radicalisation.

Bachelor number three is Counterspin Media NZ! Why not form a thruple with Kelvyn Alp and Hannah Spierer? Together you can fight the Deep State and the transhumanist agenda, and youre bound to win, because those things dont exist! Alp has lots to teach you about the moon landings, and hed love to buy you dinner with the money he makes selling weight loss pills and fraudulent vaccine passports. Maybe hell even tell you about the violent coup hes got planned. Shhh! Its a secret, but hell probably yell it to you in a livestreamed video being watched by police.

Congratulations! Youve made it to the protest! Now that youre here, why not get to know someone new? Introducing Bachelor number four, far-right white supremacist group Action Zealandia! Parliament changed security arrangements after video appeared to show these folks gaining access to a construction site in Bowen House. When theyre not helping protestors become Nazis, Action Zealandia enjoys organising terror cells, fighting hate speech laws, and grooming teenagers to join their white supremacist organisation! Action Zealandia isnt allowed to have a Facebook page any more, and Ill give you 10 guesses why.

What a friendly bunch.

Obviously, thats just a sample - theres also Billy Te Kahika, NZ Doctors Speaking Out with Science, or, more accurately, speaking without science, and a bunch of people exhausted and angry with Covid and the world in general who didnt know what else to do.

But! Were not going to be talking about police decisions in response to the protest or Speaker of the House Trevor Mallard playing games with the sound-system. Instead, were going to talk about how the protestors got there, because while there are a number of different factors that led people there, theres one thing that stands out above all else: Facebook.

Founder, CEO, and controlling shareholder of Facebook Mark Zuckerberg was determined to get people vaccinated. He and his wife, Priscilla Chan, have invested a lot of time and money into vaccination programmes, which makes it even sadder that his wee side-hustle, Facebook, turned so many people against them. Its like if Ronald McDonald became obsessed with encouraging healthy eating, but refused to give up his day job.

Facebook makes money in a similar way to a newspaper: users write content, Facebook publishes that content, they editorialise that content with an algorithm, and then they sell ad space around that content. For context, these ad sales accounted for nearly all of Facebooks $86 billion USD revenue in 2020.

Unlike a newspaper, Facebook doesnt pay its writers, fact-check its content, or spend much money on editorial oversight. The good part of this system is that you get to hear from people that newspapers wouldnt normally publish. The bad part is that you get to hear from people that newspapers wouldnt normally publish.

For example, last month was the three-year anniversary of the Christchurch shooting, which was streamed live on Facebook and seen by thousands of people.

In response to the shooting, Facebook re-established the GIFCT as an independent organisation with their frenemies Microsoft, YouTube, and Twitter. The GIFCT is focused on removing TVEC. Acronyms are fun! Unless they stand for Global Internet Forum to Counter Terrorism or Terrorist and Violent Extremist Content. Then theyre no fun at all.

The operating board of the GIFCT is made up of Facebook, Microsoft, Twitter, and YouTube (owned by Google). Its sort of like a cigarette company setting up a council to help us deal with all the lung cancer. Thanks, corporations! Where would we be without you helping us deal with the problem you cause for profit?

When one of these companies identifies a piece of content as TVEC through vague and unknowable means, they give it a hash, pop it on the database of hashes, and it goes out to the Hash Sharing Consortium. Now, the Hash Sharing Consortium might sound like a nerdy group of stoners, but it isnt. Its different.

Basically, tech companies give TVEC a digital fingerprint, so all the other major online service providers can be like, Oop, someones trying to upload a terrorist video. And they stop them from uploading the content.

People can then slightly edit that content and reupload it and then someone has to report the new content, get that new content uploaded to the hash database, and the whole process starts again. Its kind of like whack-a-mole, only instead of a mole, its the worst thing youve ever seen in your life.

The way these OSPs or Online Service Providers decide what counts as terrorist content is haphazard at best. When New Zealands Chief Censor, David Shanks, decides what content should be illegal, its an extremely delicate process. He has to decide whether sharing extremist imagery is an important part of exposing New Zealanders to the horrors of the world, or whether it may cause further harm. According to the Guardian, Youve got to protect freedom of expression, he says.

Youve got to protect this vital ability to have opinions, to spread them, to access information of any kind.

Dawid Sokoowski/Unsplash

In response to the shooting, Facebook re-established the GIFCT as an independent organisation with their frenemies Microsoft, YouTube, and Twitter, writes Robbie Nicol.

The only reason to diverge from that principle, ever, he says, is to prevent harm something he consults groups ranging from medical experts to high school students about.

Facebook has a different approach.

As of 2019, Facebook was paying people US$15 an hour to look at up to 400 posts a day of the worst stuff imaginable: beheadings, animal abuse, hate speech, and pictures of you with the flash on.

It was then up to these underpaid, traumatised workers to decide the cultural and political context of each post from countries all over the world, sometimes in languages they didnt understand. This led to genuine Nazi content being left up and people getting blocked for sharing photos of Taika Waititi from Jojo Rabbit. Thats not a joke, by the way, that actually happened.

This work is supplemented by machine learning that works perfectly. According to the Wall Street Journal, in leaked documents scientists pointed out the companys ability to detect the content in comments was bad in English, and basically non-existent elsewhere. So, as I said, perfect.

This work is also supplemented by a list of dangerous individuals and organisations, the terrorist section of which seems to be heavily copy-and-pasted from the US governments list of terrorists. This is good because the US government is totally unbiased and completely trusted by every country in the world.

And while these companies often leave up content they claim to have banned, theyre also taking down content that they shouldnt. In June 2017, YouTube announced a plan to combat terrorist content online, and it worked well. In fact, you could argue it worked too well.

To quote Wired: The quick flagging and removal of content appears successful. Unfortunately, we know this because of devastating false-positives: the removal of content used or uploaded by journalists, investigators, and organisations curating materials from conflict zones and human rights crises for use in reporting, potential future legal proceedings, and the historical record.

The thing is, censorship is hard. Its complicated and political and has enormous ramifications for democracy. Facebook isnt doing it properly, and theyre not being nearly transparent enough about how they do it.

But even worse than Facebooks inability to effectively remove harmful content is how they editorialise all the stuff thats left.

To understand why Facebook is such a great platform for radicalisation it helps to look at the changes they made to their algorithm in 2018. When I say the Facebook algorithm, I mean the code they use to decide what pieces of content they promote.

In the same way that a newspaper uses an editor to decide what goes on the front page, Facebook uses an algorithm to decide what goes at the top of your newsfeed.

Whats fun about the changes they made in 2018 is that Facebook pretended they were making these changes for the greater good. Unfortunately, internal documents suggest that instead of making these changes for the good of humankind, they were actually making the changes to increase profit, which was shocking to everyone involved.

In 2018, Facebook was worried about declining engagement". To quote the Wall Street Journal, the fear was that eventually, users might stop using Facebook altogether. A terrifying thought.

[Insert Lionel Hutz shuddering at the idea of a world without lawyers.]

So, Facebook switched things up. Now, an angry reaction was worth five times a like; a long passionate comment was worth twice a short comment saying, Good job!; an angry rant sharing the original content was worth 30 times a like and so on.

Glen Carrie/unsplash

Facebook uses an algorithm to decide what content appears at the top of your newsfeed.

In a public letter to Facebook, BuzzFeed CEO Jonah Peretti, the elder brother of Chelsea Peretti (FUN FACT!) complained that the change to the algorithm was forcing them to post increasingly controversial content to generate arguments in the comments.

In an internal report investigating the effects of the new algorithm on the politics of Poland, Facebook researchers wrote, One partys social media management team estimates that they have shifted the proportion of their posts from 50/50 positive/negative to 80 per cent negative, explicitly as a function of the change to the algorithm.

Staff at Facebook tried to come up with solutions, but again, quoting the Wall Street Journal, Mr Zuckerberg said he didnt want to pursue it if it reduced user engagement, according to the documents. What a piece of s....

The worlds most popular newspaper, Facebook, is a lawless hellscape that chooses its top stories based on how many complaints they get, and it turns out that has some negative consequences for the planet earth and the people who live there.

A landmark study in Germany looked at thousands of anti-refugee hate crimes and compared them to variables that might be relevant. These included wealth, demographics, support for far-right politics, newspaper sales, the number of refugees, history of hate crime and the number of protests. One variable stood out: Towns where Facebook use was higher than average reliably experienced more attacks on refugees.

Sometimes Facebooks ability to fuel hate crimes is even more extreme. Facebook was forced to admit that it played a role in inciting violence during the militarys genocidal campaign against the Rohingya in Myanmar. Just for some context here, inciting violence in a genocide is bad.

Similarly, in Ethiopia, an investigation by Vice said violence had been supercharged by the almost-instant and widespread sharing of hate speech and incitement to violence on Facebook, which whipped up peoples anger.

And then theres Covid-19. Again, Facebook wanted to stop the spread of misinformationthey gave free ads to the World Health Organisation and added links to accurate information on posts about the pandemic, but it wasnt enough to counteract the fundamental business model of Facebook. Publish content without editorial oversight and promote anything that drives engagement.

So, cool. Great. Facebook, the worlds most popular newspaper, might eventually stop publishing neo-Nazis like the folks at Action Zealandia, but they will actively promote anti-vaxxers because of all the people arguing in the comments, and once youre at the rally, Im sure there are some friendly dudes in brown shirts ready to say hi.

The problem is big, but, surprisingly, governments seem willing to tackle it anyway.

Law-makers in the EU proposed a law that would require online service providers to remove illegal content within one hour. It turned out to be pretty controversial, but as with most controversial actsthe French did it anyway. And this law doesnt just cover TVEC!

The BBC writes: Failure to remove content could attract a fine of up to 1.25m (1.1m). France's regulator, the Superior Council of the Audiovisual (CSA), will have the power to impose heftier fines of up to 4 per cent of global turnover for continuous and repeated violations.

For context, 4 per cent of Facebooks revenue in 2021 was nearly $5 billion USD. Thats quite a big fine.

The UK has put forward a white paper on statutory duty of care, arguing the platform that should be regulated not the content, including the design of the platform and the operation of the business. Secondly, the duty of care implies a risk assessment so that reasonably foreseeable harms are avoided where possible or mitigated.

Its written like that because the British are, unfortunately, British.

Here in New Zealand, were undergoing a review of content regulation and working on hate speech reform.

The Department of Internal Affairs has been put in charge of removing TVEC - forcing them to draw the line between radical politics and terrorism and the line between important journalism on the topic of terrorism and media used to promote terrorist acts.

Maybe thats something our Chief Censor and the Classification Office should decide, but there you go. Apparently, weve decided to give it to the Department of Internal Affairs, the department of government work that nobody else wanted to do.

Ultimately, we know that the GIFCT is insufficient, because social media companies are not going to voluntarily invest enough money to monitor what they share. We know that the Facebook algorithm is a worse editor than Rupert Murdoch, willing to throw anything on the front page that riles people up. And we know that this problem is not limited to Facebook, this s...show runs across multiple platforms that all basically run the same way.

But it took us a long time to figure out how to regulate television and radio and newspapers. And its going to take us a long time to figure out how to regulate the internet. These are enormous questions of democracy, and free speech, and protecting people from harm.

Everyone needs to be a part of this discussion.

So, if you wouldnt mind, maybe start a long pointless argument in the comments. Do all the different kinds of reactions you can think of. Reshare this video with a long speech youve copy-and-pasted from the internet.

Maybe that way we can get an important story on the front page.

White Man Behind A Desk is the work of satirist Robbie Nicol and playwright Finnius Teppett. See more at Patreon.com/WhiteManBehindADesk.

Read the rest here:
Facebook and radicalisation: how can we regulate the internet to prevent harm? - Stuff

Posted in Transhumanist | Comments Off on Facebook and radicalisation: how can we regulate the internet to prevent harm? – Stuff

The Power of Pain | Peter J. Leithart – First Things

Posted: April 6, 2022 at 1:55 am

Korean-born philosopher Byung-Chul Han completed his dissertation on Heideggers concept of Stimmung (mood) in 1994, and his early books were meditations on death and dying. Since the 2010 publication of Mdigkeitsgesellschaft (English title, The Burnout Society), now translated into a dozen languages, hes produced a steady stream of slender, poetic works of cultural commentary that track the transformations of human experience weve suffered as we adjust to the digital age. My task as a philosopher, he says, is to explain what kind of society we live in. Philosophy is truth-speaking.

In Burnout Society, Han contrasted the immunological paradigm of the twentieth century with the neuronal culture of the twenty-first. In a politics of immunology, everything foreign is simply combated. . . . even if it has no hostile intentions, even if it poses no danger, it is eliminated on the basis of its Otherness. Weve outgrown all that, we in our twenty-first-century adulthood. More and more, Han claimed, we live in a society where otherness and foreignness have disappeared. Foreign has morphed into exotic, and weve become tourists of difference. Along the way, weve outgrown barriers. The old world was marked by borders, transitions, thresholds, fences, ditches, and walls that prevent universal change and exchange. The twenty-first century began a decade early with the removal of a wallin Berlinand globalized hybridization has since displaced the regime of immunization. We now live in a world without walls.

Hans reflections havent aged well. Walls are back in style, partly in reaction to a real pandemic. But his claim that our neuronal age will be plagued by pathologies deriving from an excess of positivity is more plausible. In place of threats from the Other, we face too-much-of-the-Same, surplus positivity. Han has in mind both the homogenization of culture and the surfeit of goods, the overproduction, overachievement, and overcommunication enjoyed by globalizations winners. Excess hasnt made us happy, or even free. Were no longer subjects of a Foucauldian disciplinary society; rather, hedonism has itself become a principle of domination, represented for Han by that omnipresent data-collector, the smartphone. A new form of human existence has emerged, the self-projecting, even self-optimizing subject, driven not by external compulsion but by the internal pressure to achieve and to display achievement. Always on, we suffer from exhaustion, fatigue, and suffocationin a word, Mdigkeit or burnout.

This overstressed achievement self in the neuronal age is in the background of Hans 2021 The Palliative Society, an elegant Jeremiad against algophobia, the fear of pain that now occupies our souls. Humans have always avoided painful conditions, but today our instinct to recoil has been institutionalized. Pain has no meaning; it lies entirely outside the symbolic system. Playgrounds are cushioned or cordoned for safety. Entertainment and social media keep us in a continuous state of anesthesia. We avoid the disturbances of art, reducing beauty to the likeable. Conflict and controversial thinkers are muted. Transhumanist philosopher David Pearce hopes well eventually eliminate the soul-destroying cruelties of traditional modes of love.

Algophobia detaches us from the Other, who is inevitably a source of discomfort. Our technologies train our seeing and regulate our reactions to what we see. Film permits an exceptional degree of cold cruelty, crueler than the ancient arena because more abstract and distant. We comfortably watch real and fake violence, becoming purveyors and consumers of violence porn that has the effect of an analgesic. Insensitive to the pain of others, we adopt the passivity and indifference of the silent spectator. Images overwhelm us, but instead of shocking us to action, they erode our capacity for shock: Our attention is so fragmented that such shock is impossible. Our souls form calluses.

Overshadowing our flight from pain is a universal imperative to Be Happy. We still experience pain, but pain isnt allowed to speak; its never given room to become eloquent, to rise to heights of protest or passion. Pain is depoliticized. It retreats to soothing screens or visits the doctors office for relief. The palliative society thus brings the end of revolution. Palliation transforms the exercise of power. Once upon a time, rulers ruled by inflicting bodily pain. According to Foucault, modern disciplinary power formed human beings into cogs in the industrial machine. The genius of palliative power is that it doesnt seem to be power at all; it feels like liberation. In the quest for self-realization, the achievement selves of the palliative society cheerily exploit themselves. Power decouples from pain and repression: Smart power operates in seductive and permissive ways. We live in a smart panopticon: We are constantly asked to communicate our needs, wishes and preferences. . . . Total communication, total surveillance, pornographic exposure and panoptic surveillance coincide. Freedom and surveillance become indistinguishable.

It cant work. Happiness must be fractured to be genuine. Without pain, happiness becomes reified into a boring repetition of the same. Pain bears happiness. . . . Any intensity is painful. Passion binds pain and happiness together. As Nietzsche knew, we cant think or discover truth without pain. Algophobia keeps us from scraping against the sharp edges of reality. We know it cant work, so we seek outlets from the numbing pressure of painless happiness. Girls cut themselves. Young men seek out fight clubs and gyms. Nietzsches anesthetized last men might suddenly turn into barbaric first men, recovering the ancient joys of pain-suffering and pain-inflicting heroism.

Hans books have been described as a form of philosophical haiku, and he illuminates by offering flashes in the darkness. Often enough, what Han exposes is recognizable. I came away from The Palliative Society thinking William Jamesian thoughts, with an ecclesial twist. James hoped to end war, yet, knowing that war alone arouses passions, virtues, and strengths that cannot be achieved in any other human endeavor, he searched for a moral equivalent of war. Heres one of the many ways the church can shore up and rebuild: Remember we cant be disciples of the crucified without carrying a cross of our own. Call Christians, especially young Christians, to strenuous, grueling, and, yes, painful service to the kingdom.

Peter J. Leithart is President ofTheopolis Institute.

First Thingsdepends on its subscribers and supporters. Join the conversation and make a contribution today.

Clickhereto make a donation.

Clickhereto subscribe toFirst Things.

Read the original post:
The Power of Pain | Peter J. Leithart - First Things

Posted in Transhumanist | Comments Off on The Power of Pain | Peter J. Leithart – First Things

Is Stem Cell Research Illegal in The United States?

Posted: April 6, 2022 at 1:54 am

What Are Stem Cells?

Stem cells are cells that are capable of becoming new stem cells (self-renewal) or specialized cells that perform specific functions (differentiation).

There are 2 types of stem cells:

Another type is induced pluripotent stem cells, which are adult stem cells that are changed in a lab to be closer to embryonic stem cells, though unlike embryonic stem cells they cannot develop into every kind of cell and tissue

What Are Stem Cells Used For?

Currently, the only stem cells now used to treat disease are from blood cell-forming adult stem cells found in bone marrow.

These types of cells are used in procedures such as bone marrow transplants, as adjunct therapy for the treatment of leukemia, or to treat people with conditions such as Fanconi anemia.

Hematopoietic stem cells (stem cells that form blood and immune cells) are used for burn therapy, bone grafting, and corneal transplant tissues.

Scientists believe stem cells can be used for many different medical applications in the future, for example, by creating new heart tissue to transplant into a damaged heart to treat heart disease.

What Is Stem Cell Research?

Stem cells are being investigated in several possible roles in medicine:

Is Stem Cell Research Illegal in The United States?

Stem cell research is legal in the United States, however, there are restrictions on its funding and use.

State laws regarding research on stem cells vary widely, particularly in regard to use of embryonic stem cells. On one end of the spectrum, eight states (California, Connecticut, Illinois, Iowa, Maryland, Massachusetts,New Jersey and New York) encourage embryonic stem cell research,while on the other end of the spectrum, South Dakota strictly forbids research on embryos.

A number of states restrict research on aborted fetuses or embryos, but in some cases, research may be permitted with consent of the patient.

Read the original here:
Is Stem Cell Research Illegal in The United States?

Posted in Connecticut Stem Cells | Comments Off on Is Stem Cell Research Illegal in The United States?

The Amazing World of QC Kinetix (Doral) Regenerative Medicine in Doral, FL – Digital Journal

Posted: April 6, 2022 at 1:53 am

QC Kinetix (Doral) began operations in 2022 and operates under the aegis of QC Kinetix Group. The clinic is responding to concerns about expensive chronic pain treatment and the agony of undergoing surgery by introducing the new safe and efficient regenerative medicine. The non-surgical regenerative therapies have been tested and found effective in treating knee pain, back pain, arthritis pain, hip pain, elbow pain, shoulder pain, and joint pain. Another plus is that these non-surgical therapies produce long-lasting results, resulting in improved function and enhanced quality of life. The pain control clinic provides a zero obligation consultation to determine if the treatment is suitable.

Experienced physicians guide patients undergoing natural pain treatments at QC Kinetix (Doral). The treatment protocols targeting injuries and musculoskeletal conditions are carefully orchestrated to allow the body to self-heal and repair. With the new treatment, a lengthy recuperation period is no longer a factor.

At the QC Kinetix (Doral), patients enjoy personalized concierge-level service and treatments that promise long-lasting results. The medical providers include Sander Fernandez M.D., Milton Menco PA-C, Caitlin Sablotsky PA-C. Dr. Sander Fernandez, who is also the Medical Director and board-certified family medicine physician focused on regenerative medicine and non-surgical pain treatment, is passionate about sports medicine and musculoskeletal pain. Milton Menco, a native of Columbia, is a certified physician assistant who has served as a medical laboratory researcher and an expert in the exercise physiology field.

The regenerative medicine Doral utilizes tested and controlled regenerative therapies to achieve treatment goals like reducing inflammation, improving pain experiences, and engineering the natural repair of injured or degenerated tissues. Patients also receive the education they need concerning their conditions and the available treatment options. As a practice, the primary goal is to get patients back on their feet in the shortest time possible. Patients can visit the clinic if they experience body weakness, limited joint mobility, cramping and discomfort, swelling and stiffness, and difficulty completing daily tasks.

The successes of the biologic therapies are documented in video testimonials posted on YouTube and the clinics website. In an account involving a patient with knee pain, the patient narrates how he could not go upstairs and play basketball. After treatment, his life changed drastically, and he was able to run up and down the stairs, return to construction work, and is happy to recommend QC Kinetix (Doral) to the broader public.

To chat one-on-one with a regenerative medicine provider at QC Kinetix (Doral), call (305) 381-9000 or visit the clinic located at 730 NW 107th Ave, Suite 210, Miami, FL, 33172, United States. As a preferred regenerative medicine clinic, the facility in Doral has joined the growing list of QC Kinetix clinics.

Media Contact

Company NameQC Kinetix (Doral)Contact NameScott HootsPhone(305) 381-9000Address730 NW 107th Ave, Suite 210CityMiamiStateFLPostal Code33172CountryUnited StatesWebsitehttps://qckinetix.com/south-florida/miami/doral/

Read more from the original source:
The Amazing World of QC Kinetix (Doral) Regenerative Medicine in Doral, FL - Digital Journal

Posted in Regenerative Medicine | Comments Off on The Amazing World of QC Kinetix (Doral) Regenerative Medicine in Doral, FL – Digital Journal

Newly identified neutrophil subset is a promising therapeutic target | UIC Today – UIC Today

Posted: April 6, 2022 at 1:53 am

Intensities of protein expression of markers are shown on viSNE map as spectrum colored dots, with low in blue, high in red. (Image: Bachmaier, et al. ACS Nano)

Using a protein nanoparticle they designed, scientists at the University of Illinois Chicago have identified two distinct subtypes of neutrophils and found that one of the subtypes can be used as a drug target for inflammatory diseases.

Neutrophils are a type of white blood cell that help fight infection, clear dead cell debris, and heal tissue injury. But for people with health conditions caused by chronic inflammation, like arthritis or Crohns disease, or excessive inflammation, like sepsis, the role of neutrophils may be deleterious. Neutrophils have been described in research as also contributing to tissue damage the double-edged sword of inflammation. Unfortunately, current drugs for inflammatory diseases that target neutrophils suppress all their effects, including their anti-infection and healing functions.

The UIC team is the first to characterize neutrophils into two subsets.

Understanding the differences between these neutrophil subsets opens the door for more research on treatments that address inflammatory diseases without increasing patients risks of infections, said study author Kurt Bachmaier, assistant professor in the department of pharmacology and regenerative medicine at the College of Medicine, who led the research.

Bachmaier and his colleagues first used the nanoparticle platform, formulated from a protein called albumin, to analyze how neutrophils from bone marrow, blood, and spleen and lung tissues interact with the nanoparticle. They found that some neutrophils brought the albumin nanoparticle into the cell through a process called endocytosis, while others didnt.

The scientists labeled the subtype that readily endocytosed the nanoparticle as ANP-high, for albumin nanoparticle high. The neutrophils that did not absorb the albumin nanoparticle were labeled as ANP-low.

Further investigation with the albumin nanoparticle showed that the subtypes have different cell surface receptors and that they are functionally distinct in their helpful capacities to kill bacteria and their harmful potential to promote inflammation. ANP-highneutrophils did not help to kill bacteria but produced inordinate amounts of reactive oxygen species and inflammatory chemokines and cytokines, which contribute to inflammatory disease.

Because the ANP-high neutrophils are also the ones that captured the nanoparticle, the scientists conducted clever experiments using the albumin nanoparticle to deliver drug treatments. They filled the nanoparticle with an anti-inflammatory drug and administered it to mice with sepsis. They found that the mice treated with the drug-loaded nanoparticle had reduced signs of tissue inflammation, but that the neutrophilic host-defense was preserved.

The albumin nanoparticle, which was filled with the drug, specifically bound to ANP-high neutrophils and unloaded their cargo into the cell, stopping it in its tracks, Bachmaier said.We found ANP-high neutrophils not only in mice but also in humans, opening the possibility of neutrophil subset-specific targeted therapy for human inflammatory diseases.

Science can be a bit like magic by targeting only the ANP-high neutrophils, we stopped the out-of-control inflammation while preserving the bacteria-fighting inflammation of these Janus-like cells, said senior author Asrar Malik, Schweppe Family Distinguished Professor and head of the department of pharmacology and regenerative medicine.

These findings are reported in the article Albumin Nanoparticle Endocytosing Subset of Neutrophils for Precision Therapeutic Targeting of Inflammatory Tissue Injury, which is published in ACS Nano, a scientific publication of the American Chemical Society and the primary nanotechnology journal.

Co-authors of the article are Andrew Stuart, Amitabha Mukhopadhyay, Sreeparna Chakraborty, Zhigang Hong, Li Wang, Yoshikazu Tsukasaki, Mark Maienschein-Cline, Balaji Ganesh, Prasad Kanteti and Jalees Rehman.

Here is the original post:
Newly identified neutrophil subset is a promising therapeutic target | UIC Today - UIC Today

Posted in Regenerative Medicine | Comments Off on Newly identified neutrophil subset is a promising therapeutic target | UIC Today – UIC Today

Penn Researchers Discover New Cell Type in Human Lung with Regenerative Properties – Penn Medicine

Posted: April 6, 2022 at 1:53 am

Human ES cell derived RASC (respiratory airway secretory cell) transitioning to an Alveolar type 2 cell over time in culture

PHILADELPHIA A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.

The researchers, who report their findings today in Nature, analyzed human lung tissue to identify the new cells, which they call respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that RASCs have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of RASCshinting that correcting this disruption could be a good way to treat COPD.

COPD is a devastating and common disease, yet we really dont understand the cellular biology of why or how some patients develop it. Identifying new cell types, in particular new progenitor cells, that are injured in COPD could really accelerate the development of new treatments, said study first author Maria Basil, MD, PhD, an instructor of Pulmonary Medicine.

COPD typically features progressive damage to and loss of alveoli, exacerbated by chronic inflammation. It is estimated to affect approximately 10 percent of people in some parts of the United States and causes about 3 million deaths every year around the world. Patients often are prescribed steroid anti-inflammatory drugs and/or oxygen therapy, but these treatments can only slow the disease process rather than stop or reverse it. Progress in understanding COPD has been gradual in part because micethe standard lab animalhave lungs that lack key features of human lungs.

In the new study, Morrisey and his team uncovered evidence of RASCs while examining gene-activity signatures of lung cells sampled from healthy human donors. They soon recognized that RASCs, which dont exist in mouse lungs, are secretory cells that reside near alveoli and produce proteins needed for the fluid lining of the airway.

With studies like this were starting to get a sense, at the cell-biology level, of what is really happening in this very prevalent disease, said senior author Edward Morrisey, PhD, the Robinette Foundation Professor of Medicine, a professor of Cell and Developmental Biology, and director of the Penn-CHOP Lung Biology Institute at Penn Medicine.

Observations of gene-activity similarities between RASCs and an important progenitor cell in alveoli called AT2 cells led the team to a further discovery: RASCs, in addition to their secretory function, serve as predecessors for AT2 cellsregenerating them to maintain the AT2 population and keep alveoli healthy.

AT2 cells are known to become abnormal in COPD and other lung diseases, and the researchers found evidence that defects in RASCs might be an upstream cause of those abnormalities. In lung tissue from people with COPD, as well as from people without COPD who have a history of smoking, they observed many AT2 cells that were altered in a way that hinted at a faulty RASC-to-AT2 transformation.

More research is needed, Morrisey said, but the findings point to the possibility of future COPD treatments that work by restoring the normal RASC-to-AT2 differentiation processor even by replenishing the normal RASC population in damaged lungs.

The research was supported by the National Institutes of Health (HL148857, HL087825, HL134745, HL132999, 5T32HL007586-35, 5R03HL135227-02, K23 HL121406, K08 HL150226, DK047967, HL152960, R35HL135816, P30DK072482, U01HL152978), the BREATH Consortium/Longfunds of the Netherlands, the Parker B. Francis Foundation, and GlaxoSmithKline.

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $9.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 52,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.

See original here:
Penn Researchers Discover New Cell Type in Human Lung with Regenerative Properties - Penn Medicine

Posted in Regenerative Medicine | Comments Off on Penn Researchers Discover New Cell Type in Human Lung with Regenerative Properties – Penn Medicine

Stem Cell Assay Market | Viability/Cytotoxicity Assay Segment Estimated to Account for the Largest Share – Here’s Why – MDC Research – GlobeNewswire

Posted: April 6, 2022 at 1:53 am

Pune, April 04, 2022 (GLOBE NEWSWIRE) -- Stem cells refer to the undifferentiated biological cells that differentiate into specialized cells and divide to produce more stem cells. They are found in multicellular organisms and are of two types mainly embryonic stem cells and adult stem cells. These cells are present in areas in the body such as bone marrow, adipose tissue, and blood. Stem cells are also taken from umbilical cord blood. The stem cell population in the body is maintained through two processes, which include obligatory asymmetric replication and stochastic differentiation. Stem cells play an important role in the natural healing process of the body and introduction of stem cells has shown positive results in the treatment of many diseases such as cancer. The significance of stem cell assays lies in the fact that they are used for various processes such as viability or cytotoxicity studying, isolation and purification of stem cells, cell identification, cell proliferation, and cell differentiation for research purposes. In the case of stem cell transplant, initially, the embryonic stem cells are specialized into necessary adult cell type. Then, these cells are used to replace the tissue that is damaged due to any disease or injury.

The growth of thestem cell assays market corresponds with that of the biotechnology and biopharmaceutical industries, as these form significant end users for stem cell research products. The continuation of this trend the growth of the end-user base has compelled a number of companies to launch new products and invest in stem cell-based therapies. The growing incidence of cancer is increasing across the globe due to the rise in the aging population and changing lifestyle habits. This in turn, is accelerating the demand for anticancer drugs and therapies globally. The growing prevalence of various diseases such as cancer and cardiovascular diseases and the potential of stem cell therapy in the management of these diseases is projected to boost the growth of the Stem Cell Assay Market. Stem cell transplant replaces the neurons damaged by spinal cord injury, Alzheimers disease, and stroke. These factors are expected to drive the growth of the Stem Cell Assay Market.

Get a Sample Copy of the Report https://www.marketdatacentre.com/sample/8

The development in embryonic & adult stem cell assay will be beneficial to the global market. The increasing adoption of stem cell therapies has significantly helped the market to grow substantially. The continuously increasing healthcare expenditure and funding by several governments and private players in the field of stem cell research have boosted the market. Moreover, technological advancement in the instruments has driven the demand for stem cell assays in the market.Emergence of microfluidics in stem cell research, high growth potential of single stem cell analysis sequencing, and untapped potential in emerging markets offer favourable growth opportunities.

The Global Stem Cell Assay Market is segmented on the basis of Product, Cell types, Application, Assay, and region. Based on product market is segmented into Instruments, Reagents and kits. The instruments segment accounted for the largest share of global Stem Cell Assay Market. Some of the major factors driving the growth of this segment include ongoing technological innovations in stem cell instruments and the rising number of stem cell research activities.

Based on cell types market is divided into Adult Stem Cells (Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Hematopoietic Stem Cells, and Umbilical Cord Stem Cells) and Human Embryonic Stem Cells. By application, the market is segmented into regenerative medicine and therapy development, drug discovery and development, and clinical research. The regenerative medicine and therapy development segment accounted for the largest share of the global Stem Cell Assay market. The increasing demand for stem cells in the development of various types of cell therapies and growing regenerative medicine industry across the world are factors driving this market segment.

Based on Assay, The market is segmented into Cell Identification Assays, Viability Assays, Apoptosis Assays, Isolation & Purification Assays, and Others. The viability segment holds the largest market share during the forecast period. The factors that can be attributed to the widespread use of viability assays in stem cell research activities. Based, on the end user the market is divided into Government research institutes, Private Research Institutes and Industry Research.

Regional Analysis

Stem cell assay market is regionally segmented into North America, Asia-Pacific, Europe, and Rest of the World. North America followed by Europe had the biggest market for Stem cell based assays. In North America the large share of the geographical segment is attributed to factors such as the increasing incidence of chronic diseases and improved life sciences, research infrastructure and increasing funds for R&D in that region.

The European market is not far behind North America and is projected to show promising growth in the upcoming period. Factors such as increasing consciousness regarding cell based assays and increased adoption of R&D activities is propelling the markets growth rate.

Asia-Pacific market is expected to grow in the upcoming years. Growth in Asia-Pacific is due to rising infrastructural developments, growing funds in R&D by various public and private organizations is enhancing the market. The growing no. of Cancer cases, rising toxicity for examination and drug identification are escalating the stem cell assays market.

Speak to Our Research Analyst https://www.marketdatacentre.com/analyst/8

COMPANY PROFILES (Business Overview, Products/Services Offered, Financial Performance, R&D Intensity, Marketing & Sales Intensity, Recent Developments, Analyst Corner)*

At MDC Research, we offer research solutions to help businesses break the barriers of doubt or uncertainties when they plan to expand their growth. Our researchers compile data and information that help chief executive officers decide which growth opportunities in a market to pursue.

MDC Research is known for conducting well-researched reports, and the expertise of our researchers contributes to the outstanding quality of our reports. MDC Research enables businesses to make impactful decisions by blending innovation and analytical thinking. Our unique blend of these two skills assures you access to the most complete and up-to-date information about your industry.

MDC Research has a wealth of experience using the latest methodologies to develop reports for a wide range of clients in diverse markets. Our commitment to delivering high-quality research and creating innovative reports is one of the reasons why MDC Research is such a trusted name in the business world today.

Buy the Premium Report https://www.marketdatacentre.com/checkout/8

Recent Developments

GE Healthcare inaugurated a new testing centre to enhance its research and manufacturing capabilities.

Danaher Company launched ClearLLAb 10C systems for flow cytometry labs.

PerkinElmer completed acquisition of Cisbio Bioassays.

Read Overview of the Report https://www.marketdatacentre.com/stem-cell-assay-market-8

About MDC:

Market Data Centre (Subsidiary of Yellow Bricks Global Services Private Limited)

Market Data Centre offers complete solutions for market research reports in miscellaneous businesses.These decisions making process depend on wider and systematic extremely important information created through extensive study as well as the most recent trends going on in the industry.The company also attempts to offer much better customer-friendly services and appropriate business information to achieve our clients ideas.

Read more:
Stem Cell Assay Market | Viability/Cytotoxicity Assay Segment Estimated to Account for the Largest Share - Here's Why - MDC Research - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on Stem Cell Assay Market | Viability/Cytotoxicity Assay Segment Estimated to Account for the Largest Share – Here’s Why – MDC Research – GlobeNewswire

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference – GlobeNewswire

Posted: April 6, 2022 at 1:53 am

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.

As a leading sponsor of this years conference, we are excited to share new research on our innovative product portfolio and hear from other thought leaders about advances in wound care, said Katie Mowry, Assistant Vice President, Research and Development for Organogenesis.

Attendees of this year's event are encouraged to visit the Organogenesis-supported breakfast symposium, "Investigating the Reliability and Transferability of Current RCT Based on Real-World Evidence" held Thursday, April 7, 2022 from 7:30 to 9:00 a.m. MST in room 224 at the Phoenix Convention Center. This panel discussion features Vickie R. Driver, DPM, MS, FACFAS FAAWC, Robert S. Kirsner, MD, PhD, FAAD, William Marston, MD, and Oscar M. Alvarez, PhD, CCT, FAPWCA, and will discuss how randomized controlled trials (RTCs) based on real-world evidence translates to evaluating wound care therapies.

The Organogenesis-sponsored Innovation Theatre lunch, Practical Utilization of Skin Substitutes for Chronic Wounds Using Prognostic Patient Indicators will be held Thursday, April 7, 2022 from 12:00 to 1:30 p.m. MST in room 224. This lunch will feature a presentation by Andrew J. Rader, DPM, FAENS, FACFAOM, FAPWCA, FACCWS of Memorial Hospital Wound Care and Nicholas Todd, DPM, FACFAS of Palo Alto Medical Foundation, who will discuss the use of prognostic patient indicators to determine the appropriate course of action for treating chronic wounds.

Attendees are encouraged to visit the Organogenesis exhibit hall booth (#703) to learn more about the latest advanced wound care products and latest studies. Organogenesis tissue regeneration specialists will be available to discuss the full portfolio of Organogenesis solutions that address wounds from head to toe.

The booth will be open during the following hours:

POSTER PRESENTATIONS OF INTEREST INCLUDE:

A Single Center Pilot Study Investigating the Effects of a Native Cross-Linked Extra Cellular Matrix with PHMB Antimicrobial Barrier to Manage Chronic Lower Extremity Wounds Exhibiting Bacterial Contamination as Determined by a Novel Violet-Light Imaging SystemWindy Cole, DPM, CWSP1, Janina Krumbeck, PhD

An Alternative Approach to the Management of Wounds Secondary to Diagnosis or Treatment of Skin CancersDaniel Kapp, MD, Laura Pfendler, PT, DPT, CWS

Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Placental Membrane for Use in Pressure InjuriesOscar M. Alvarez, PhD, Michael L. Sabolinski, MD

Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Cadaveric Skin Allograft for Use in Pressure InjuriesOscar M. Alvarez, PhD, Michael L. Sabolinski, MD

ABSTRACTS OF INTEREST INCLUDE:

Characterization of a Micronized Native Collagen Wound Matrix And Its Effectiveness In a Swine Full-Thickness Wound Healing Model Justin T. Avery, Vivek P. Raut, and Katie C. Mowry

Hypothermic Storage of Amnion and Chorion Membranes Retain Native Tissue CharacteristicsKatrina A. Harmon Ph.D.1 and Katie C. Mowry Ph.D.1

Robust Durability and Resistance to Degradation of a Native Type I Collagen Matrix with PHMB in vitroKatrina A. Harmon, Ph.D.1 and Katie C. Mowry Ph.D.1

About Organogenesis Holdings Inc.Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Companys Annual Report on Form 10-K for the year ended December 31, 2021. Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only to the date of this release, and Organogenesis undertakes no obligations to update or revise these statements, except as may be required by law.

Continued here:
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference – GlobeNewswire

Page 516«..1020..515516517518..530540..»